接受皮肤冠状动脉干预的老年ACS患者的性别差异,接受Ticagrelor 60 mg和90 mg的治疗
Raffaele Piccolo1, Angelo Laino2, Antonio Pio Vitale2
1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. Raffaele.Piccolo@unina.it.
Journal of thrombosis and thrombolysis
|November 16, 2025
概括
提卡格勒罗尔60毫克和90毫克剂量在患有急性冠状动脉综合征 (ACS) 的老年患者中显示出类似的P2Y12反应单位,而不论性别. 使用60毫克剂量的血水平较低.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在早期急性冠状动脉综合征 (ACS) 管理中,对于蒂卡格勒勒的药理动力学和药理动力学存在有限的性别特异性数据.
- 提卡格勒勒是一种P2Y12抑制剂,用于接受皮肤冠状动脉干预 (PCI) 的ACS患者.
研究的目的:
- 为了对PLINY THE ELDER试验进行基于性别的二次分析.
- 在老年男性和女性ACS患者中,比较Ticagrelor 60 mg和90 mg的药理学和药理学概况.
主要方法:
- 一个随机交叉试验的后期分析 (PLINY THE ELDER,NCT04739384).
- 在治疗后14天使用VerifyNow-P2Y12评估剂前P2Y12反应单位 (PRU).
- 通过聚合计评估血小板抑制,并测量了血中蒂卡格勒水平.
主要成果:
- 无论是男性还是女性,都没有观察到蒂卡格勒罗60毫克和90毫克之间PRU的显著差异 (p>0.05对所有比较).
- 对于PRU,没有发现基于性别的相互作用 (p对相互作用>0.05).
- 与60毫克剂量相比,Ticagrelor的血水平在两性中都显著降低,而90毫克剂量在两性中都显著降低 (女性p < 0.001,男性p < 0.002).
结论:
- 60毫克和90毫克的提卡格勒罗在老年ACS患者中,无论性别如何,都能提供可比的血小板抑制.
- 与标准90毫克剂量相比,减少60毫克剂量导致血度较低.
相关概念视频
01:30Acute Coronary Syndrome I: Introduction
753
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
753
01:30Acute Coronary Syndrome III: Diagnostic Studies
200
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
200
01:28Acute Coronary Syndrome IV: Interprofessional Care
205
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
205
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
01:15Drug Dosing: Geriatric Patients
215
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
215
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
333
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
333